Digital health company Omada files for US IPO
FILE PHOTO: A street sign for Wall Street is seen outside the New York Stock Exchange (NYSE) in New York City, New York, U.S., July 19, 2021. REUTERS/Andrew Kelly/File Photo
(Reuters) -Virtual chronic care provider Omada Health has filed to go public in the United States, the latest in a string of healthcare listings expected this year.
While U.S. President Donald Trump's tariff whiplash has roiled markets and cast a shadow on new listings, companies in sectors perceived as less sensitive to economic headwinds are pushing ahead with their initial public offerings.
Omada did not disclose the details as to how much it plans to raise from its IPO.
The San Francisco, California-based company, which last raised $192 million in a Series E funding round in 2022, reported a 38% increase in revenue to $169.8 million for 2024, according to its IPO paperwork.
For the first quarter of 2025, the company posted a 56.6% year-on-year jump in revenue to $55 million.
Omada has applied to list its common stock on the Nasdaq under the symbol "OMDA".
Healthcare IPOs on U.S. exchanges have fetched $7.1 billion in 2024, compared with $2.8 billion a year earlier, according to data compiled by LSEG.
Hinge Health, which provides digital exercise therapy programs to help people manage and overcome muscle and joint pain, filed for its long-sought IPO in March.
J.P.Morgan, Goldman Sachs, Morgan Stanley and Barclays are among the underwriters for Omada's offering.
(Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Anil D'Silva and Shilpi Majumdar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Financial 15 Split Corp. declares $0.08058 preferred dividend
- Trump taps White House adviser Overton to lead FDA
- Lyntris opens at $15.50, below IPO price of $17.50
Create E-mail Alert Related Categories
ReutersRelated Entities
Goldman Sachs, Donald J. Trump, Morgan Stanley, Barclays, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share